Amneal Pharmaceuticals' Biosimilars, Specialty Growth Reshape Earnings Profile, Oppenheimer Says

MT Newswires Live09-24

Amneal Pharmaceuticals (AMRX) is at a fundamental inflection as its differentiated launches, vertically integrated biosimilars, and Specialty business growth reshape its earnings profile, Oppenheimer said in a note Wednesday.

The brokerage said it estimates 9% growth in 2026 and about $3.1 billion of revenue by 2030, supported by 20 to 30 annual launches across differentiated dosage forms, with Lanreotide's high-barrier injectable opportunity expected to approach $100 million in annual sales over time.

The company's $750 million Kashiv acquisition creates a scaled biosimilars platform, Oppenheimer said, adding that it models biosimilar revenue rising to $1.1 billion by 2030 from $122 million in 2026.

The brokerage said Crexont can become the company's next major Specialty brand, and can more than offset Rytary erosion and drive high single-digit Specialty growth with incremental margins.

Oppenheimer initiated coverage of the stock with an outperform rating and a $27 price target.

Price: 19.01, Change: -0.49, Percent Change: -2.51

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment